Medtronic strengthens pacemaker line:
This article was originally published in Clinica
Medtronic has entered into a non-exclusive sublicence with wireless data communication technology company LifeSync Corporation to gain its patent portfolio. The sublicence will allow Medtronic to use LifeSync's wireless ECG data communication system in connection with implantable devices for cardiac pacing, defibrillation, neurostimulation, gastrostimulation and urological stimulation. Fort Lauderdale, Florida-based LifeSync said that it grants sublicences for its intellectual property to third parties for uses that it does not intend to internally develop and commercialise, in a statement made on August 15. This is the second deal Medtronic has struck up in a week to boost, in particular, its range of pacemakers. The company bought MRI safety patents from Biophan on August 9 (see Clinica No 1269, p 10).
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.